RxDoctor Payments Data

Noreen Murphy Bowens

Nurse Practitioner · Newark, DENPI 1669869210

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.9% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,260in general payments, 2019–2025

Across 211 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$834
  • Pfizer$727
  • Novartis$603
  • Merck$487
  • Boehringer Ingelheim$476
  • E.r. Squibb & Sons, L.L.C.$423
  • plus $710 from 8 others

What the payments were for

  • Food & beverage$4,12797%
  • Education$1333%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,260 in reported general payments places this provider in the 90th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban21$33,062
Repatha SureclickEvolocumab18$28,587
EntrestoSacubitril/Valsartan14$23,987
EliquisApixaban11$17,952
Ezetimibe84$2,179
Atorvastatin Calcium109$1,475
Rosuvastatin Calcium65$1,264
Metoprolol Succinate51$713
Carvedilol37$542
Amiodarone Hcl24$453
Amlodipine Besylate57$387
Metoprolol Tartrate44$315
ClopidogrelClopidogrel Bisulfate17$297
Lisinopril27$211
Losartan Potassium16$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$834$33,06221 claims
NovartisEntresto$603$23,98714 claims
PfizerEliquis$727$17,95211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 487 nurse practitioner providers in Delaware.

Other nurse practitioner in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →